Dermatomyositis Clinical Trial
Official title:
An Open-label Extension to the Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis
Verified date | July 2023 |
Source | Kezar Life Sciences, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open-label study to evaluate the long-term efficacy and safety of KZR-616 in patients with active PM or DM who completed the double-blind treatment period of Study KZR-616-003, up to and including the Week 32 Visit, prior to the first dose of open-label KZR-616.
Status | Completed |
Enrollment | 18 |
Est. completion date | June 12, 2023 |
Est. primary completion date | March 10, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Must have successfully completed Study KZR-616-003 through Week 32, including the Week 32 Visit assessments - Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test prior to the first dose of KZR-616 in KZR-616-003E, and must agree to continue to use a highly effective method of birth control until completion of the study. - Male patients must continue to use an effective contraception method for 1 week following their last dose of KZR-616 or be congenitally or surgically sterile. Exclusion Criteria: - Have clinical evidence of significant unstable or uncontrolled diseases other than the disease under study, that in the opinion of the Investigator or Sponsor/designee, could confound the results of the study, put the patient at undue risk, or interfere with protocol adherence. - Has participated in any clinical study other than KZR-616-003 between the Week 32 Visit of Study KZR-616-003 and the first study visit of KZR-616-003E, if they are not on the same calendar day. - Are females who are breastfeeding or who plan to become pregnant during the study, or who are actively trying to conceive at the time of signing of the informed consent form. - Have hypersensitivity to KZR-616 or any of its excipients. |
Country | Name | City | State |
---|---|---|---|
United States | KZR Research Site | Ann Arbor | Michigan |
United States | KZR Research Site | Austin | Texas |
United States | KZR Research Site | Baltimore | Maryland |
United States | KZR Research Site | Beverly Hills | California |
United States | KZR Research Site | Duncansville | Pennsylvania |
United States | KZR Research Site | Irvine | California |
United States | KZR Research Site | Kansas City | Kansas |
Lead Sponsor | Collaborator |
---|---|
Kezar Life Sciences, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Peak Pruritus Numeric Rating Scale Pruritis Numerical Rating Scale [NRS] | For DM patients, the Peak Pruritus Numeric Rating Scale ranges from a score of 0 to 10, with 0 representing no itch and 10 representing the worst itch imaginable during the worst moment within a 24-hour recall period. | 60 weeks | |
Other | Incidence, nature, and severity of treatment-emergent adverse events (TEAEs) with the causal relationship assessed by the investigator graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). | Safety | 60 weeks | |
Primary | Total Improvement Score (TIS) | Mean change in TIS over time for all patients, for patients with DM only, for patients with PM only, and for patients with a myositis-associated antibody or myositis-specific antibody. | 80 weeks | |
Secondary | Total Improvement Score (TIS) response | Proportion of patients by TIS response (minimal response = TIS = 20, moderate response = TIS = 40, major response = TIS = 60) |
80 weeks | |
Secondary | International Myositis Assessment and Clinical Studies Group (IMACS) Definition of Improvement (DOI) | Proportion of patients meeting IMACS definition of improvement (DOI) over time for patients with baseline core set measures. | 80 weeks | |
Secondary | International Myositis Assessment and Clinical Studies Group (IMACS) individual Core Set Activity Measures (CSAMs) | Mean change and mean percentage change over time in the IMACS individual CSAMs and CSDMs, stratified by all patients and patients with myositis-associated or myositis-specific antibody. | 80 weeks | |
Secondary | Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) | Mean change over time in the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) for all patients with DM, and for patients with DM who have active skin manifestations at baseline of Study KZR-616-003E. | 60 weeks | |
Secondary | Corticosteroid and non-corticosteroid immunosuppressants | Change in proportion and dose of corticosteroid and non-corticosteroid immunosuppressants during Study KZR-616-003E for all patients, and for patients taking corticosteroids or non-corticosteroid immunosuppressants at baseline of Study KZR-616-003E. | 60 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05833711 -
Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
|
Phase 2 | |
Completed |
NCT01906372 -
Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
|
Phase 2 | |
Completed |
NCT01813617 -
Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis
|
N/A | |
Completed |
NCT01165008 -
Anakinra in Myositis
|
Phase 2/Phase 3 | |
Completed |
NCT00004357 -
Absorption of Corticosteroids in Children With Juvenile Dermatomyositis
|
Phase 2 | |
Recruiting |
NCT05832034 -
Add-on Intravenous Immunoglobulins in Early Myositis
|
Phase 2 | |
Recruiting |
NCT05979441 -
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
|
Phase 3 | |
Not yet recruiting |
NCT05027152 -
Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties
|
N/A | |
Active, not recruiting |
NCT04723303 -
Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)
|
Early Phase 1 | |
Completed |
NCT03267277 -
Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05437263 -
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
|
Phase 3 | |
Active, not recruiting |
NCT04044690 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)
|
Phase 3 | |
Recruiting |
NCT05523167 -
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06004817 -
Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis
|
||
Recruiting |
NCT03324152 -
Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis
|
N/A | |
Completed |
NCT02043548 -
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
|
Phase 2 | |
Completed |
NCT03414086 -
Predictor of Clinical Response to Acthar in Myositis
|
||
Recruiting |
NCT03293615 -
Exercise Capacity of Patients With Dermatomyosis
|
N/A | |
Completed |
NCT06002750 -
Evaluation of Tp-e Interval and Tp-e/QT Ratio in Dermatomyositis and Analysis of Their Relationship With Inflammation
|
||
Completed |
NCT02612857 -
Trial of IMO-8400 in Adult Patients With Dermatomyositis
|
Phase 2 |